Ann: Incannex to Acquire APIRx Pharmaceuticals, page-51

what a joke.
we are talking about 10% dilution. We did more than 10% increase in our market cap on a single day several days last week. Just off market action. This is a pretty naive comment.

Management have been extremely astute in getting this done as an all scrip deal with next to no dilution. If it was $93M cash, well that would be a challenge but this is nothing. Any one of these verticals could justify a unicorn market cap. Have you had a look at some of the regulatory status. Some of these have completed Phase 2 clinical trials! We have a Billion dollar market cap off our OSA Phase 2A trial!!!

And for some pretty important conditions like glaucoma, IBS etc. I think this will transpire to be an incredible acquisition and as usual the Australian market has completely missed the ball